Increased interest in CariSolv due to the Corona pandemic

One consequence of the Corona pandemic is that the dental industry is facing a major shift in terms of caries treatment. Traditional treatment of caries attacks is done with drilling and repair. In connection with drilling in the tooth, aerosol is formed which radically increases the spread of infection during treatment. The dental industry is now facing a major challenge in how caries should be treated as simply and gently as possible for patient in the future.  

RLS Global has, based on the situation, increased demand for CariSolv. CariSolv is based on the same unique buffered hypochlorite technology platform as other products in the portfolio. The gel is applied to the caries and with an instrument, the dentist scrapes away the damaged tissue. In other words, no (or minimal) drilling is required to minimize caries attack and aerosol formation is a very limited problem. RLS has decided to continue the production of CariSolv at least until May 2021. The company has so far received two orders from UK, which will be delivered in July. RLS is also in dialogue with several countries in Europe that have shown interest in the product.

In January, RLS announced that the company had made the strategic decision to focus on wound management and ChloraSolv. As a result, PeriSolv was sold to an external partner, however CariSolv remains in the company’s ownership. Important to note – RLS’s future strategy and priorities are still wound management and to further develop the unique buffered hypochlorite technology for new indication areas.

It is satisfying to be able to support the dental industry in these challenging times. CariSolv is a product with good potential, but so far it has not been recognized by the market, says Karin Fischer, CEO RLS Global. Karin continues, ‘in the coming months, we will evaluate the future potential of the product and take the long-term decision for the product’.

Trading place and Certified Advisor

RLS Global’s shares has been listed on the Nasdaq First North Growth Market since 17th May, 2017 and trading takes place under the short name RLS. Certified Advisor is Redeye Aktiebolag, phone: +46 8 121 576 90, email: certifiedadviser@redeye.se. During the period 2012 - 2017, the company was listed on Aktietorget.


Contact information

Karin Fischer, CEO
E-mail:
karin.fischer@rlsglobal.se
Telephone: +46 702-48 46 51

Eva Jagenheim, CFO
E-mail:
eva.jagenheim@rlsglobal.se
Telephone: +46 31 780 68 20

About RLS Global AB
RLS Global AB is a medical technology company within Life Science. Based on the company's unique hypochlorite platform, RLS Global develop product within wound care. RLS Global has a portfolio of strong brands, including ChloraSolv® and CariSolv®. The company is listed on Nasdaq First North Growth Market with Redeye Aktiebolag as the Certified Advisor, phone: +46 8 121 576 90, email: certifiedadviser@redeye.se. Read more at www.rls.global

About Us

For many years, RLS Global has worked with Oral Care specialists, pioneering new therapies for Oral Care and their patients. We are now taking another major step toward easier and more effective care within Wound Care. We will continue to work with Healthcare Professionals to ensure to develop a treatment that further helps deliver the best care for each patient. The method is clinically proven and saves the patient a lot of suffering. Our focus is on caring for patients, developing efficient and safe products that offer gentle treatment methods.

Subscribe

Documents & Links